文献速递肺外科

非小细胞肺癌患者接受新辅助纳武利尤单抗或纳武利尤单抗联合伊匹木单抗后的手术结局

Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer.
PubMed 文献 · J Thorac Cardiovasc Surg · 2022-01-23

研究评估非小细胞肺癌患者接受新辅助纳武利尤单抗或纳武利尤单抗联合伊匹木单抗后的围手术期结局,并与化疗后或直接手术患者比较。44例I-IIIA期患者随机分配至纳武利尤单抗组(n=23)或联合伊匹木单抗组(n=21)。结果显示术后并发症率与化疗后或直接手术相当,作者认为新辅助免疫治疗后手术总体安全有效。

要点

  • 纳武利尤单抗组91%按方案切除,联合组76%按方案切除。
  • 术后并发症率与化疗后或直接手术相当。

核心结论

  • 新辅助纳武利尤单抗或纳武利尤单抗联合伊匹木单抗后手术总体安全有效,围手术期结局与化疗后或直接手术相似。

研究设计与样本

  • 44例I-IIIA期非小细胞肺癌患者随机分配至纳武利尤单抗组(3 mg/kg静脉注射,第1、15、29天;n=23)或纳武利尤单抗联合伊匹木单抗组(伊匹木单抗1 mg/kg静脉注射第1天;n=21),计划在末次新辅助纳武利尤单抗后3至6周行根治性手术。
  • 同期完成直接切除或化疗后切除的患者作为对照。

主要发现

  • 纳武利尤单抗组21例(91%)按方案切除,1例方案外手术,1例未切除(毒性相关)。
  • 纳武利尤单抗联合伊匹木单抗组16例(76%)按方案切除,1例方案外手术,4例未切除(非毒性相关)。
  • 中位手术时间31天;术式包括全肺切除2例(5%)、肺叶切除33例(89%)、肺段切除和楔形切除各1例(3%)。
  • 入路为开胸27例(73%)、胸腔镜7例(19%)、机器人辅助3例(8%);微创手术中转率17%(2/12)。
  • 所有37例均实现R0切除;肺部并发症9例(24%)、心脏4例(11%)、肠道2例(5%)、神经1例(3%)、伤口1例(3%);30天和90天死亡率分别为0%和2.7%(n=1)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Surgical outcomes for non-small cell lung cancer after neoadjuvant immune checkpoint inhibitors continue to be debated. We assessed perioperative outcomes of patients treated with Nivolumab or Nivolumab plus Ipilimumab (NEOSTAR) and compared them with patients treated with chemotherapy or previously untreated patients with stage I-IIIA non-small cell lung cancer. METHODS: Forty-four patients with stage I to IIIA non-small cell lung cancer (American Joint Committee on Cancer Staging Manual, seventh edition) were randomized to nivolumab (N; 3 mg/kg intravenously on days 1, 15, and 29; n = 23) or nivolumab with ipilimumab (NI; I, 1 mg/kg intravenously on day 1; n = 21). Curative-intent operations were planned between 3 and 6 weeks after the last dose of neoadjuvant N. Patients who completed resection upfront or after chemotherapy from the same time period were used as comparison. RESULTS: In the N arm, 21 (91%) were resected on-trial, 1 underwent surgery off-trial, and one was not resected (toxicity-related). In the NI arm, 16 (76%) resections were performed on-trial, one off-trial, and 4 were not resected (none toxicity-related). Median time to operation was 31 days, and consisted of 2 (5%) pneumonectomies, 33 (89%) lobectomies, and 1 (3%) each of segmentectomy and wedge resection. The approach was 27 (73%) thoracotomy, 7 (19%) thoracoscopy, and 3 (8%) robotic-assisted. Conversion occurred in 17% (n = 2/12) of minimally invasive cases. All 37 achieved R0 resection. Pulmonary, cardiac, enteric, neurologic, and wound complications occurred in 9 (24%), 4 (11%), 2 (5%), 1 (3%), and 1 (3%) patient, respectively. The 30- and 90-day mortality rate was 0% and 2.7% (n = 1), respectively. Postoperative complication rates were comparable with lung resection upfront or after chemotherapy. CONCLUSIONS: Operating after neoadjuvant N or NI is overall safe and effective and yields perioperative outcomes similar to those achieved after chemotherapy or upfront resection.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Sepesi B, Zhou N, William WN, et al. Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022. PMID: 35190177. doi:10.1016/j.jtcvs.2022.01.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。